Safety and Performance of a Novel Defibrillation Lead for LBBAP: Primary Results of LEADR LBBAP
Authors, Journal, Affiliations, Type, DOI
- Authors: Pugazhendhi Vijayaraman, Xingbin Liu, Russell Denman, Edward J. Schloss, Zachary I. Whinnett, Jordana Kron, Marek Jastrzębski, John S. Zakaib, Walter P. Abhayaratna, François Philippon, Muhammad R. Afzal, Parash Pokharel, James Burrell, Jocelyn Tanner, Tessa Geelen, Megan L. Platner, Kiah Butler, Pamela K. Mason, George H. Crossley, on behalf of the LEADR LBBAP Trial Investigators
- Journal: Heart Rhythm 2026;23(10):2083–2092
- Affiliations: Geisinger Heart Institute (Wilkes-Barre, PA); West China Hospital, Sichuan University (Chengdu, China); The Prince Charles Hospital (Brisbane, Australia); The Christ Hospital (Cincinnati, OH); Imperial College Healthcare NHS Trust and Imperial College London (London, UK); Virginia Commonwealth University (Richmond, VA); Jagiellonian University Medical College (Kraków, Poland); Minneapolis Heart Institute Foundation (Minneapolis, MN); Canberra Hospital (Canberra, Australia); Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University (Québec, Canada); The Ohio State University Wexner Medical Center (Columbus, OH); Medtronic, Inc (Minneapolis, MN); Medtronic Bakken Research Center (Maastricht, the Netherlands); University of Virginia Medical Center (Charlottesville, VA); Vanderbilt Heart & Vascular Institute (Nashville, TN)
- Type: Prospective, multicentre, single-arm, non-randomised global clinical trial (NCT04863664)
- DOI: 10.1016/j.hrthm.2025.10.028
Overview
LEADR LBBAP is the first prospective trial of the 4.7-F lumenless OmniaSecure defibrillation lead when implanted for left bundle branch area pacing. Of 307 implant attempts, 293 (95.4%) met the protocol definition of success; all 162 patients in the primary defibrillation cohort were successfully defibrillated at implant (95% CI 97.7–100), and freedom from lead-related major complications at 3 months was 97.9% (95% CI 95.8–100). Electrical parameters were stable through a mean follow-up of 2.6 months, with no lead fractures or oversensing-related adverse events. The trial supports a single-lead strategy that combines defibrillation with LBBAP and provides the short-term safety and efficacy basis for placing this lead in the conduction system rather than the standard right ventricular position. The later final-results report extends follow-up to 12 months (sources/leadr-lbbap-hrs-2025); the right-ventricular LEADR trial provides 3-year data for the same lead platform (sources/leadr-final-circep-2026).
Keywords
Conduction system pacing; Left bundle branch area pacing; Defibrillation lead; Cardiac resynchronization; Defibrillation efficacy
Key Takeaways
Study design and population
- Prospective, multicentre, single-arm, non-randomised global trial at 24 centres with 51 implanting physicians, April 2024 to March 2025; 323 enrolled, 16 excluded before an implant attempt, 307 attempts.
- Geographic distribution: 178 (55.1%) North America, 82 (25.4%) Asia and Australia, 35 (10.8%) Europe, 28 (8.7%) China.
- Mean age 64.9 ± 12.2 years; 88 women (28.7%); body mass index 28.4 ± 6.1 kg/m².
- Primary prevention indication in 254 (82.7%); ischaemic cardiomyopathy 117 (38.1%), non-ischaemic 143 (46.6%), hypertrophic 22 (7.2%); diabetes 127 (41.4%); atrial fibrillation 78 (25.4%); left bundle branch block 134 (43.6%), intraventricular conduction delay 28 (9.1%), right bundle branch block 35 (11.4%).
- Device type: CRT-D 145 (49.5%), dual-chamber ICD 100 (34.1%), single-chamber ICD 48 (16.4%).
Implant procedure and LBBAP confirmation
- Successful implant per protocol in 293/307 (95.4%).
- The C315-His catheter was used in 218 (74.4%); 231 patients (78.8%) required only one study lead.
- LBBAP success could be met by electrical criteria, deep septal position on sheath ventriculography, or both. The most common physician-reported criterion was Qr or qR in V1 with recommended left ventricular activation time <100 ms (150 patients, 51.2%); deep septal position by contrast injection was reported in 94 (32.1%); diagnostic QRS transition in 23 (7.8%); left bundle branch potential in 6 (2.0%); V6–V1 interpeak >33 ms in 19 (6.5%).
- The defibrillation coil was fully in the right ventricle in 275 (93.9%); when not, the estimated coil length in the right atrium was 9.0 ± 3.7 mm.
Primary efficacy: defibrillation at implant
- The primary efficacy cohort comprised 162 consecutive patients. Defibrillation success was 100% (162/162; 95% CI 97.7–100), exceeding the prespecified 88% threshold.
- First-induction success occurred in 159 patients (98.1%); 134 (82.7%) were defibrillated with an 18 J shock and 25 (15.4%) with a safety margin of 10 J below maximum output; median energy 18 J.
- Three patients required troubleshooting: one succeeded after a second induced episode, one after one lead reposition, and one after two repositions.
- An additional 33 patients underwent elective defibrillation testing per protocol; all were successfully defibrillated.
- No correlation was found between defibrillation coil position and defibrillation testing results, but few failures were available for analysis.
Electrical and sensing performance
- Pacing capture threshold was 0.6 ± 0.3 V at 0.4 ms at implant and remained stable through follow-up.
- R-wave amplitude was 8.9 ± 4.8 mV at implant, rose to 10.9 ± 5.4 mV at 3 months, and remained stable at 6 months.
- Pacing impedance was 507 ± 120 Ω at implant, 365.3 ± 51.0 Ω at 3 months, and stable through 6 months; right ventricular coil impedance was 74 ± 25.9 Ω at implant and 70.3 ± 8.3 Ω at 3 months.
- At discharge, 89.0% of patients had right ventricular sensitivity programmed to 0.45 mV or a less sensitive setting.
- There were four inappropriate shocks in three patients, all due to high ventricular rates from atrial tachycardia or atrial fibrillation; there were no inappropriate shocks or adverse events from P- or T-wave oversensing through follow-up.
Primary safety
- Five study lead–related major complications occurred in five patients: two lead dislodgements, one device connection issue (impedance >3000 Ω), one high right ventricular pacing threshold, and one undersensing (low R-wave amplitude). All five resulted in revision to a non-study lead.
- Freedom from study lead–related major complications was 97.9% at 3 months (95% CI 95.8–100) and 97.2% at 6 months (n = 42; 95% CI 94.8–99.7).
- There were no lead fractures, no oversensing-related major complications, and no inappropriate shocks from oversensing.
- Seven deaths occurred; none were adjudicated as causally related to the study lead.
LOT-CRT and QRS outcomes
- In the LOT-CRT cohort, intrinsic QRS was 170.3 ± 29.8 ms and LBBAP-only paced QRS at implant was 156.6 ± 27.0 ms.
- In ICD-indicated patients, intrinsic QRS was 139.4 ± 27.7 ms and paced QRS was 152.5 ± 22.2 ms, longer than the intrinsic QRS in this subgroup.
- The primary report does not present 6-month functional outcomes; those are in the final-results report (sources/leadr-lbbap-hrs-2025).
Interpretation
- A single 4.7-F lumenless defibrillation lead can deliver defibrillation and LBBAP without a separate right ventricular pace/sense lead.
- Defibrillation efficacy and short-term electrical performance were similar to the right-ventricular LEADR experience: 18 J first-shock success was 82.7% in LEADR LBBAP versus 82.8% in LEADR; coil-in-atrium rates were 6.1% versus 4.5%.
- The lead's small diameter and lumenless construction may reduce hardware, infection risk and tricuspid interference, but the trial was not powered for those outcomes.
- The study population included 22 patients (7.2%) with hypertrophic cardiomyopathy; the results are not specific to hypertrophic cardiomyopathy or apical aneurysm.
Limitations of the document
- Single-arm, non-randomised, non-comparative — no direct comparison with standard right ventricular defibrillation leads or with biventricular pacing.
- Short follow-up — mean 2.6 ± 2.5 months; 6-month data available in only 42 patients. Long-term lead durability, extraction and tricuspid interaction remain unknown.
- LBBAP success was physician-reported per protocol, not centrally adjudicated. The protocol definition includes deep septal pacing, not necessarily left bundle branch capture; the quality of LBB capture was not a primary objective.
- Defibrillation testing was not routine in all patients. The primary efficacy cohort was 162 consecutive patients; 33 additional patients underwent elective testing.
- Industry sponsorship — Medtronic funded the trial; several authors are employees or shareholders, and multiple investigators report Medtronic honoraria or consultancy.
- No long-term comparison with the right-ventricular LEADR trial — the two trials share a lead platform but differ in implant position, follow-up and endpoints.
- Limited generalisability to hypertrophic cardiomyopathy with apical aneurysm — only 7.2% of the population had hypertrophic cardiomyopathy, and patients with apical thrombus or recent ventricular tachycardia storm were not specifically studied.
Key Concepts Mentioned
- concepts/Left-Bundle-Branch-Area-Pacing — the pacing strategy and lead position
- concepts/LOT-CRT — LBBAP plus coronary sinus left ventricular pacing
- concepts/Conduction-System-Pacing — the wider family of physiological pacing
- concepts/Cardiac-Resynchronization-Therapy — the CRT-D indication
- entities/ICD — the device platform and lead technology
Key Entities Mentioned
- Medtronic — manufacturer and sponsor; OmniaSecure defibrillation lead
- LEADR LBBAP Trial Investigators — multicentre trial group
- Geisinger Heart Institute — coordinating centre
- SelectSecure 3830 — the predicate lumenless pacing lead on which the OmniaSecure design is based
Wiki Pages Updated
- Created:
wiki/sources/leadr-lbbap-primary-hrs-2026.md - Updated:
wiki/concepts/LBBAP-Outcomes.md - Updated:
wiki/entities/ICD.md - Updated:
wiki/sourceindex.md - Updated:
wiki/wikiindex.md - Updated:
log.md